Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. More Details
Reasonable growth potential average dividend payer.
Share Price & News
How has Bristol-Myers Squibb's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BMY is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: BMY's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: BMY underperformed the US Pharmaceuticals industry which returned 7% over the past year.
Return vs Market: BMY underperformed the US Market which returned 22.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Bristol-Myers Squibb's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHave Insiders Been Selling Bristol-Myers Squibb Company (NYSE:BMY) Shares?
3 weeks ago | Simply Wall StEarnings Beat: Bristol-Myers Squibb Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
1 month ago | Simply Wall StBristol-Myers Squibb's (NYSE:BMY) Stock Price Has Reduced 11% In The Past Five Years
Is Bristol-Myers Squibb undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BMY ($61.78) is trading below our estimate of fair value ($136.12)
Significantly Below Fair Value: BMY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BMY is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: BMY is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BMY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BMY is good value based on its PB Ratio (2.8x) compared to the US Pharmaceuticals industry average (3.7x).
How is Bristol-Myers Squibb forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BMY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: BMY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BMY's is expected to become profitable in the next 3 years.
Revenue vs Market: BMY's revenue (4.9% per year) is forecast to grow slower than the US market (10.2% per year).
High Growth Revenue: BMY's revenue (4.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BMY's Return on Equity is forecast to be high in 3 years time (39.8%)
How has Bristol-Myers Squibb performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BMY is currently unprofitable.
Growing Profit Margin: BMY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BMY is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare BMY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BMY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).
Return on Equity
High ROE: BMY has a negative Return on Equity (-0.056%), as it is currently unprofitable.
How is Bristol-Myers Squibb's financial position?
Financial Position Analysis
Short Term Liabilities: BMY's short term assets ($34.3B) exceed its short term liabilities ($20.5B).
Long Term Liabilities: BMY's short term assets ($34.3B) do not cover its long term liabilities ($54.8B).
Debt to Equity History and Analysis
Debt Level: BMY's debt to equity ratio (89.5%) is considered high.
Reducing Debt: BMY's debt to equity ratio has increased from 47.7% to 89.5% over the past 5 years.
Debt Coverage: BMY's debt is well covered by operating cash flow (27.6%).
Interest Coverage: BMY is unprofitable, therefore interest payments are not well covered by earnings.
What is Bristol-Myers Squibb current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BMY's dividend (2.91%) is higher than the bottom 25% of dividend payers in the US market (1.48%).
High Dividend: BMY's dividend (2.91%) is low compared to the top 25% of dividend payers in the US market (4.11%).
Stability and Growth of Payments
Stable Dividend: BMY's dividends per share have been stable in the past 10 years.
Growing Dividend: BMY's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: BMY is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: BMY's dividends in 3 years are forecast to be well covered by earnings (25.2% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Giovanni Caforio (55 yo)
Dr. Giovanni Caforio, M.D. serves as the Chief Executive Officer at Bristol-Myers Squibb Belgium NV/SA. Dr. Caforio has been the Chief Executive Officer of Bristol-Myers Squibb Farmacêutica Portuguesa, SA ...
CEO Compensation Analysis
Compensation vs Market: Giovanni's total compensation ($USD18.77M) is above average for companies of similar size in the US market ($USD10.98M).
Compensation vs Earnings: Giovanni's compensation has been consistent with company performance over the past year.
|Chairman of the Board & CEO||5.58yrs||US$18.77m||0.020% |
|Executive VP & CFO||1.08yrs||US$5.49m||0.0024% |
|Executive VP & General Counsel||13.83yrs||US$7.52m||0.019% |
|Executive VP & Chief Commercialization Officer||2.92yrs||US$5.74m||0.00093% |
|Executive VP and President of Research & Early Development||1.08yrs||US$5.17m||no data|
|Executive VP & Chief Information Officer||8.92yrs||no data||0.0056% |
|VP & Head of Investor Relations||no data||no data||no data|
|Senior VP||2.92yrs||no data||0.00071% |
|Executive VP & Chief Human Resources Officer||4.5yrs||no data||0.0023% |
|Executive VP and President of Global Product Development & Supply||3.67yrs||US$4.13m||0.0012% |
|Head of US Drug Makers - India||6.42yrs||no data||no data|
|Head of Oncology Development||4.42yrs||no data||no data|
Experienced Management: BMY's management team is considered experienced (4.4 years average tenure).
|Chairman of the Board & CEO||5.58yrs||US$18.77m||0.020% |
|Independent Director||1.08yrs||US$48.41k||0.00047% |
|Independent Director||8.92yrs||US$315.00k||no data|
|Lead Independent Director||3.58yrs||US$393.24k||no data|
|Independent Director||7.42yrs||US$353.85k||0.00098% |
|Independent Director||3.83yrs||US$354.81k||0.000010% |
|Independent Director||1.08yrs||US$78.41k||no data|
|Independent Director||3.83yrs||US$332.50k||0.00050% |
|Independent Director||4.67yrs||US$354.81k||no data|
|Independent Director||3.83yrs||US$337.50k||0.0012% |
|Independent Director||1.08yrs||US$78.41k||0.00030% |
|Independent Director||2.92yrs||US$335.17k||no data|
Experienced Board: BMY's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BMY insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bristol-Myers Squibb Company's company bio, employee growth, exchange listings and data sources
- Name: Bristol-Myers Squibb Company
- Ticker: BMY
- Exchange: NYSE
- Founded: 1887
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$139.607b
- Shares outstanding: 2.26b
- Website: https://www.bms.com
Number of Employees
- Bristol-Myers Squibb Company
- 430 East 29th Street
- 14th Floor
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BMY||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jan 1968|
|BMY *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jan 1968|
|BRM||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1968|
|BRM||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Jan 1968|
|BMY||SWX (SIX Swiss Exchange)||Yes||Common Stock||CH||CHF||Jan 1968|
|0R1F||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 1968|
|BRM||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Jan 1968|
|BMYS||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Jan 1968|
|BMY||BVL (Bolsa de Valores de Lima)||Yes||Common Stock||PE||USD||Jan 1968|
|BMY||BASE (Buenos Aires Stock Exchange)||CEDEAR EACH 3 REP 1||AR||ARS||Mar 2009|
|BMYB34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EA REPR 1 COM SHS||BR||BRL||Aug 2012|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therap...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/03 23:49|
|End of Day Share Price||2020/12/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.